| Ytd | 1199.09% | |
| 1y | -23.21% |
| Open | 4.54 | Prev Close | 4.56 | Low | 4.27 | High | 4.54 | Mkt Cap | 6.74M |
| Vol | 8.99K | Avg Vol | 9.89K | EPS | -7.13 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.50 | 200-d Avg | 7.00 | 1yr Est | 0.00 |
CURX News
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday&#
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday'
Gainers InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday&#
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
NEW YORK, May 22, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an invest
NEW YORK, May 18, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an invest
Curanex Pharmaceuticals (NASDAQ:CURX) reported quarterly losses of $(0.11) per share. This is a 1000
Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for
Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for
NEW YORK, May 12, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an invest
LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights l
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve
Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer,
Curanex highlights patient cases suggesting its lead candidate may aid cachexia and severe disease r
Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential r
Curanex highlights a patient case showing symptomatic improvement, supporting its strategic focus on
Curanex Pharmaceuticals (NASDAQ: CURX - Get Free Report) and Zomedica (OTCMKTS:ZOMDF - Get Free Repo
Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jeric
Curanex expands pipeline with cancer cachexia, advances Phyto-N toward IND, and reports preclinical
Curanex expands pipeline with cancer cachexia, advances Phyto-N toward IND, and reports preclinical
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broade
Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at
New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission
New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals C
Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho,
Curanex Pharmaceuticals shares surged in after-hours trading after the company completed a GMP-compl
Curanex Pharmaceuticals shares surged in after-hours trading after the company completed a GMP-compl
Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho,
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“C
